Paul Tudor Jones Verve Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$29 Billion
Q1 2025

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 36,975 shares of VERV stock, worth $411,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,975

Holding current value

$411,531

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$4.57 - $8.63 $168,975 - $319,094	36,975 New	36,975 $168,000
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $4,862 - $8,685	-1,105 Reduced 2.59%	41,544 $201,000
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $4,403 - $11,830	925 Added 2.22%	42,649 $208,000
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $451,036 - $749,363	41,724 New	41,724 $554,000
Q3 2023 Nov 15, 2023	BUY	$11.42 - $20.82 $10,289 - $18,758	901 Added 2.92%	31,744 $420,000
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $119,139 - $177,726	-8,931 Reduced 22.45%	30,843 $578,000
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $192,892 - $323,870	13,489 Added 51.32%	39,774 $574,000
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $469,187 - $1.07 Million	26,285 New	26,285 $509,000
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $269,766 - $561,084	-24,216 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $506,598 - $953,141	24,216 New	24,216 $553,000
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $363,584 - $584,816	-7,904 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $252,295 - $476,216	7,904 New	7,904 $476,000

Others Institutions Holding VERV

# of Institutions

201

Shares Held

85.1M

Call Options Held

350K

Put Options Held

186K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account